Top 50 Ai For Drug Discovery in Europe

The startup specializes in Pharma 3.0 drug discovery, utilizing advanced computational methods and machine learning algorithms to identify potential drug candidates more efficiently. This approach addresses the high costs and lengthy timelines associated with traditional pharmaceutical research and development.

The startup develops an AI-enabled platform that identifies novel synthetic lethal targets and biomarkers for cancer treatment. By creating small molecule therapeutic drug candidates, the platform facilitates the discovery and development of targeted therapies for specific cancer types.

Receptor.AI uses artificial intelligence to accelerate the drug discovery process. Their platform helps researchers identify and develop new drug candidates more efficiently.

XtalPi is a pharmaceutical technology company that utilizes computational modeling and machine learning to predict drug interactions and properties, followed by experimental validation in wet labs. This approach reduces the time and cost associated with traditional drug discovery processes, enabling faster development of effective therapeutics.

This company provides a physics-driven generative AI platform for drug discovery, specializing in mapping the dynamic conformational landscape of therapeutic targets. Its technology uncovers previously inaccessible binding pockets to design novel drug-like molecules and predict binding affinity with experimental accuracy. The platform accelerates preclinical development by screening candidates for toxicity, ADME properties, and potential drug repurposing opportunities.

Kuano provides quantum simulation and artificial intelligence solutions specifically tailored for drug design applications. The company leverages advanced computational methods to enhance the discovery process for new therapeutics. This technology assists pharmaceutical researchers in exploring molecular interactions with greater precision.

This company develops immunotherapies by utilizing immune organoids and artificial intelligence to design drugs that function effectively in humans from the initial stages. Their platform aims to accelerate drug discovery timelines and reduce development costs by testing candidates in realistic, patient-matched disease models. By integrating human data early, they seek to deliver safer, more effective therapies with fewer side effects across diverse populations.

Totus Medicines utilizes AI/ML and DNA-encoded covalent library technology to discover small molecule drugs targeting previously undruggable disease pathways. Their platform enables high-throughput drug discovery, significantly increasing the speed and efficiency of developing therapeutics for advanced cancers and other serious conditions.

The startup develops a drug discovery platform that combines artificial intelligence and synthetic biology to digitize natural diversity and identify potential drug candidates based on their functions. This approach aims to make the discovery of new therapeutics for cancer, metabolic diseases, and infectious diseases more predictable and cost-effective.

The startup develops a drug discovery platform that integrates artificial intelligence with a wet-lab validation system to identify new mitophagy-activating drug candidates for Alzheimer's disease. By investigating the molecular mechanisms of aging and age-related diseases, the company aims to enhance both lifespan and health span for patients.

Boltz provides an AI‑driven platform that accelerates drug discovery by enabling rapid, large‑scale virtual screening of small molecules and protein designs, delivering near‑FEP affinity predictions up to 1,000× faster than traditional methods. Its modular agents—Boltz‑1 for all‑atom co‑folding, Boltz‑2 for ultra‑fast affinity prediction, and BoltzGen for universal binder design—integrate experimental feedback to continuously improve model accuracy for pharmaceutical, biotech, and academic research.

Dioclea Labs develops AI-powered sampling algorithms that improve the accuracy of predicting experimental results in drug discovery. Their technology enhances predictions of binding affinity and efficiency, accelerating the identification of promising drug candidates.

Lemna provides an AI platform that uses a geometric transformer to model protein‑protein and protein‑ligand interactions at atomic resolution, delivering explainable predictions of binding interfaces and molecular hotspots. The cloud‑based service lets pharmaceutical and biotech researchers prioritize targets, assess druggability, and design molecules with minimal data requirements, integrating via API and tools like PeSTo and CARBonAra.

The startup specializes in protein engineering using machine learning techniques to accelerate drug development processes. By optimizing protein design, the company aims to enhance the efficacy and reduce the time required for new therapeutic solutions.

Helical AI provides a Virtual AI Lab platform that bridges the gap between machine learning models and biological decision-making in R&D. The platform offers biologists self-serve tools for designing and evaluating in-silico experiments, while ML engineers gain a production environment for model personalization and alignment. This integrated approach accelerates discovery in areas like target identification and therapeutic design, leading to higher hit rates for pharmaceutical research teams.

The startup has developed a biomolecule copying technology that enables the efficient production and replication of microarrays, facilitating research in tumor and autoimmune therapies. This technology simplifies the complex interactions of the immune system, enhancing capabilities in diagnostics, vaccine development, and lead screening.

This startup uses AI to analyze previously unexamined regions of the human genome, translating complex genetic data into actionable insights. Their technology helps healthcare providers enhance patient care and accelerates drug discovery by revealing new genetic associations.

The startup is developing a proprietary artificial intelligence platform for creating patient-level models of autoimmune diseases, aimed at enhancing the drug discovery process in immunology and inflammation. This technology enables more precise targeting of treatments, improving patient outcomes in the management of autoimmune conditions.

Healx utilizes generative AI to enhance and combine existing compounds for the rapid discovery of treatments for rare diseases, addressing the lack of effective therapies for over 90% of the 10,000 known rare diseases. By de-risking the drug development process, Healx increases the likelihood of successful outcomes and accelerates the delivery of new therapies to patients.

Rayca Precision provides a secure research environment (SRE) that enables healthcare organizations to share and analyze sensitive patient data without it leaving its original location. This platform uses machine learning pipelines for applications such as biomarker discovery, genotype-phenotype prediction, and treatment response modeling, facilitating secure data collaboration and advanced analytics in healthcare.

The startup develops clinically validated software applications that utilize artificial intelligence to analyze real-world data, enhancing patient outcomes and supporting the discovery of new medicines. By connecting patients, clinicians, and researchers, the platform generates extensive phenotypic databases that enable discovery research companies to maximize revenue in the healthcare sector.

Orakl Oncology utilizes an AI-native predictive platform integrating patient-derived biology and real-world data to advance oncology drug development. This platform uncovers novel drug targets and accurately predicts patient responses to streamline discovery and clinical translation. The company partners with pharmaceutical firms to de-risk clinical trials, improve R&D efficiency, and accelerate the delivery of new therapeutic options to cancer patients.

METiS Therapeutics utilizes artificial intelligence, machine learning, and molecular dynamics to develop targeted delivery systems for small molecules and gene therapies. The company addresses the challenge of efficient drug delivery by creating lipid nanoparticles that demonstrate high delivery efficiency and safety profiles across multiple organ systems.

Ingenix provides a multimodal generative AI platform that builds digital twins of drug candidates by integrating genomics, proteomics, imaging, literature, and electronic health records across molecular to population scales. The system delivers detailed, interpretable predictions of clinical efficacy, safety endpoints, and adverse events, and supports natural‑language “what‑if” queries for trial design and candidate prioritization. It is aimed at pre‑clinical, strategic R&D, and clinical development teams in pharmaceutical and biotechnology companies.

Nabla Bio utilizes biologically informed machine learning and experimental technologies to design antibodies with atomic precision, targeting complex disease mechanisms such as GPCRs and ion channels. The platform enhances drug manufacturability, safety, and efficacy by integrating AI-driven design with empirical measurement of human-relevant drug properties.

Causaly is a generative AI platform that automates knowledge extraction from vast biomedical literature, enabling researchers to identify validated targets and novel biomarkers with high precision. By reducing research time from months to minutes, it enhances productivity by up to 90%, allowing scientists to focus on innovative drug discovery.

CHARM Therapeutics utilizes its proprietary DragonFold technology, which employs 3D deep learning for protein-ligand co-folding, to develop small molecule inhibitors targeting previously undruggable proteins associated with cancer and other diseases. By addressing the challenge of the vast majority of the human proteome remaining undruggable, the company aims to create transformative therapies for patients with high unmet medical needs.

Turbine's Simulated Cell™ platform utilizes AI to predict biological responses by simulating experiments across various models, including engineered cell lines and patient samples. This technology accelerates drug development by generating actionable insights in half the time of traditional methods, enabling researchers to identify optimal experimental pathways for novel cancer therapies.

AIVIVO LTD develops artificial intelligence systems that generate multi-modal omics data to create OrganoMaps, which connect disease biology with treatment interventions at the organ level. This approach enables the development of targeted medicines for patients by providing insights into organ-specific disease mechanisms.

Relation Therapeutics utilizes single-cell multi-omics, functional assays, and machine learning to identify druggable targets and develop therapies for severe diseases, starting with osteoporosis. By integrating high-resolution biological data directly from patient tissue, the company aims to enhance understanding of disease mechanisms and improve treatment outcomes.

Sortera Bio generates millions of sequence-function pairs per experiment using its Deep Screening platform. This data accelerates AI-driven biologics discovery by providing comprehensive datasets for identifying novel drug leads, even against challenging targets like membrane proteins.

Abzu utilizes its proprietary explainable AI technology, the QLattice®, to analyze complex datasets in pharmaceutical research, providing transparent insights that enhance drug discovery and development. By delivering clear and interpretable models, Abzu addresses the challenge of opaque AI systems, enabling researchers to understand the underlying factors driving their data-driven decisions.

Qubit Pharmaceuticals develops novel drug candidates using a quantum-enabled foundation model and platform that integrates physics, AI, and quantum computing for high-precision molecular simulation. Their ATLAS platform accelerates drug candidate selection and optimization by providing superior accuracy in molecular modeling compared to traditional methods. This technology targets complex disease pathways in oncology, inflammation, and pandemic response by enabling the design of treatments for previously intractable targets.

Transition Bio operates an end‑to‑end condensate drug discovery platform that integrates droplet microfluidics with advanced cellular imaging. The platform generates molecular‑level data on how chemical compounds affect condensate systems, enabling precise assessment of drug candidates. Machine learning and AI are applied to optimize chemical matter and accelerate novel therapeutic development.

Infinimol provides an integrated, AI-driven drug discovery platform to accelerate early-stage pharmaceutical research. The platform offers virtual screening of billions of compounds, property-driven lead optimization, and generation of novel molecules against specific targets. It utilizes advanced semantic search capabilities within a modular pipeline architecture for efficient hit group identification.

Bioptimus is developing a universal AI foundation model specifically for biological research, enabling researchers to leverage large-scale data analysis and predictive modeling. This technology addresses the challenge of slow and fragmented discovery processes in biomedicine by providing a cohesive platform for accelerating insights and innovations.

Kvantify develops a computational drug discovery platform that utilizes proprietary physics-based methods and bespoke algorithms to enhance the quality of compound screening for biotech and pharmaceutical companies. By integrating classical and quantum computing techniques, the platform accelerates research processes and reduces the risks associated with drug development.

Antiverse utilizes machine learning and advanced cell line engineering to design target-specific antibody libraries for challenging drug targets, including G-protein coupled receptors and ion channels. The platform accelerates the antibody discovery process, enabling the development of functional therapeutics within six months, addressing the lengthy timelines typically associated with traditional drug development methods.

Aignostics develops AI foundation models for precision medicine, specializing in processing complex biomedical and digital pathology data. The company offers products for tumor microenvironment profiling and services for target discovery and translational research. Their platform enables the development of validated digital diagnostic tools to improve drug development and patient outcomes.

Vincere Biosciences develops novel therapeutics targeting Parkinson's disease and age-related kidney disease, utilizing proprietary AI/ML tools to design and optimize drug candidates. Backed by over $2.7 million in grants from organizations like the NIH and the Michael J. Fox Foundation, the company aims to initiate human trials for its first molecule within 18 months.

The startup develops analytics software that integrates multi-omic data with AI analytics to enhance drug candidate identification and biomarker discovery. This technology enables precision medicine organizations to streamline research processes and significantly reduce time-to-market for new treatments.

BioStrand utilizes its patented LENSai™ Integrated Intelligence Technology to analyze multi-omics data and accelerate antibody drug discovery through advanced computational methods. This technology addresses the inefficiencies in identifying and prioritizing lead drug candidates by providing rapid insights into drug interactions and predicted efficacy.

SilicoGene offers a no-code platform for health-tech teams to manage the entire AI lifecycle in drug discovery, enabling users to prepare bioinformatics data, train models, and deploy them efficiently. The platform provides on-demand access to cost-effective GPUs and ensures data security through HIPAA-compliant infrastructure, facilitating rapid deployment of AI solutions in real-world applications.

CoSyne Therapeutics applies polymathic Artificial Intelligence to accelerate precision medicine drug discovery, focusing specifically on underserved brain diseases. The company utilizes advanced computational methods to identify novel therapeutic targets and develop treatments for complex neurological conditions. This approach aims to significantly advance the pipeline for brain cancer and other challenging brain disorders.

Ensocell is a biotechnology company developing next-generation precision biologics for autoimmune and fibrotic diseases. The company utilizes the ENSO AI platform to identify molecular targets and predict disease biology with high precision. This approach informs the design of tailored therapeutics with improved clinical success potential.

Poolbeg Pharma is a biopharmaceutical company focused on developing treatments for infectious diseases and metabolic conditions, utilizing artificial intelligence to enhance drug discovery efficiency. The company addresses the critical unmet medical needs in areas such as cancer immunotherapy-induced cytokine release syndrome and obesity through its robust pipeline of clinical assets.

Ahead is a biotech company that employs a proprietary platform for accelerated drug development through biomarker identification and predictive modeling. This technology reduces the time and costs associated with bringing new therapeutics to market by improving candidate selection and minimizing clinical trial failures.

Healx provides an AI‑powered platform that integrates genomics, phenotypic and clinical data to identify and prioritize repurposed or optimized compounds for rare disease indications. The system automates in silico screening, predictive efficacy and safety modeling, and workflow orchestration to move candidates from computational prediction to preclinical validation, lowering discovery costs and timelines. It is offered to pharmaceutical, biotech and research consortium partners seeking to expand rare‑disease pipelines.

Tessel Biosciences develops virtual tissues to accelerate drug design and discovery. Their platform enables researchers to model complex biological systems outside of traditional in vivo or in vitro settings. This approach provides a scalable method for testing therapeutic candidates with greater predictive accuracy.

Deepflare provides an AI platform that predicts T-cell immunogenicity beyond simple binding affinity for antigen design. This platform accelerates discovery and de-risks drug pipelines by delivering superior candidate predictions with high accuracy. Users can design, iterate, and receive optimized candidates within 24 hours using integrated computational biology tools.